Patient Home Monitoring Corp.

August 05, 2015 09:00 ET

PHM Announces Updated Investor Presentation for Upcoming Roadshow, M&A Update, and TSX Approval of the Share Buy Back Plan

LOS ANGELES, CALIFORNIA--(Marketwired - Aug. 5, 2015) -


Patient Home Monitoring (PHM) (TSX VENTURE:PHM), a profitable company focused on rolling-up annuity-based healthcare service companies in the U.S., today released an updated investor presentation for meetings scheduled with institutional shareholders during the month of August. The presentation reiterates revenue guidance for 2015 and provides organic revenue growth projections for Sleep Management through the end of 2015. The new presentation can be found on

Update on M&A Pipeline

The M&A team continues to build the pipeline for potential acquisitions and is actively engaged in early discussions with dozens of potential sellers. There are 4 outstanding LOIs with annualized revenues totaling $62 million that PHM continues to work towards closing. The PHM M&A team is actively renegotiating these acquisitions to all cash transactions and has successfully reduced the shares issued in closing the Legacy Oxygen transaction by 854,043 shares for $894,520 in consideration. PHM may issue a small portion of the consideration in shares to recruit experienced management.

Share Buy Back (NCIB)

TSX Venture Exchange has been advised by the Company that pursuant to a Notice of Intention to make a Normal Course Issuer Bid dated July 29, 2015, it may repurchase for cancellation, up to 14,511,207 shares in its own capital stock. The purchases are to be made through the facilities of TSX Venture Exchange, or other recognized marketplaces, during the period August 7, 2015 to August 6, 2016.

While PHM does not generally comment on specific shareholders, the Company has been asked to provide clarity to the market on the holdings of Michael Dalsin and Roger Greene. Mr. Dalsin and Mr. Greene have transferred shares to the Healthcare Special Opportunities Fund (TSX:MDS.u), sold shares to satisfy a tax liability and have elected to retain shares in their personal names that weren't eligible for transfer to the fund. They remain active non-executive board members and advisors to the company, as well as significant shareholders both individually and though their restricted stock in the Healthcare Special Opportunities Fund (TSX:MDS.u). Please refer to SEDI for accurate details and information about their holdings.

"We are committed to continuing to close acquisitions and as large shareholders we are very focused on limiting share dilution," said CEO Casey Hoyt. "We expect to achieve growth by acquisition with the resulting cross-selling growth. This quarter, our fourth fiscal quarter, we will make investments into natural organic growth, the third prong of our growth strategy. This expansion will have the initial effect of increasing expenses for the quarter. We expect to see a return on this investment the following quarter."

"I want to continue to urge our shareholders to focus on our financial results and quarter-over-quarter growth. For both the Board of Directors, as well as the executive team, that is our priority. By having the ability reduce total shares outstanding by 5% through the NCIB, we also look to boost EPS."

To address questions that it has received from investors and as a result of a review by the BCSC, we are issuing this press release to clarify our disclosure. PHM has updated the financial derivative section of the balance sheet increasing shareholder's equity by $18,996,075, decreasing conversion liability warrants by $18,996,075 the effect of which impacted non-operating net profit after tax (including IFRS treatment of financial derivatives) by $909,492 on the financial statements, as a result of the share price on the last day of the quarter, which is a non-cash, non-operating, IFRS accounting treatment expense, for the second quarter ending March 31, 2015 as well as providing clarifying footnotes and more comprehensive descriptions. The updated filings can now be found on Sedar.

About PHM

The explosive growth in the number of elderly patients in the US healthcare market is creating pressure to provide more efficient delivery systems. Healthcare providers, such as hospitals, physicians and pharmacies, are seeking partners that can offer a range of products and services that improve outcomes, reduce hospital readmissions, and help control costs. PHM fills this need by delivering a growing number of specialized products and services to achieve these goals. PHM is a positive cash flow and profitable company that serves patients with heart disease and other chronic health conditions, this operation is a platform for acquisitions and organic growth. PHM is focused on a highly fragmented and developing market of small privately-held companies servicing chronically ill patients with multiple disease states caused mainly by age and obesity. Because of the new and highly fragmented nature of the market, PHM is actively working to identify and evaluate profitable, annuity-based companies to acquire their patient databases and technical expertise at favorable prices. PHM's post acquisition organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient's services and making life easier for the patient. The expected result is growing EPS with each acquisition and growing revenue and profits from the cross selling efforts.

Forward Looking Statements

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws, including the approval of the normal course issuer bid by the Exchange and the number, if any, and prices at which shares are purchased during the bid period. Implicit in this information, particularly in respect of the future outlook of PHM and anticipated events or results, are assumptions based on beliefs of PHM's senior management as well as information currently available to it. While these assumptions were considered reasonable by PHM at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue acquisitions, the ability of PHM to close acquisitions and effectively integrate such acquisitions, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, difficulty integrating newly acquired businesses, low profit market segments as well as general economic, market and business conditions, and could differ materially from what is currently expected. There can be no assurance that forward-looking statements will prove to be accurate. The forward-looking statements contained herein are presented for the purposes of assisting investors in understanding PHM's plan, objectives and goals and may not be appropriate for other purposes. Accordingly, readers should not place undue reliance on forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information